News

The study enrolled 31 subjects diagnosed with impaired glucose tolerance (IGT), with a with a mean age of 52 years and a body mass index of 33. The

MitoCare will begin in January 2011 and will be conducted by a 16 partner consortium led by Trophos. MitoCare will evaluate the safety and efficacy of TRO40303 in

Watson Pharmaceuticals has confirmed that Watson Laboratories has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market Hydromorphone

The agreement is designed to enable substantial advances in existing manufacturing process for the benefit of both partners. bluebird bio president and CEO Nick Leschly said that Genethon

Skinvisible concluded the development phase for the hemorrhoid formulation using Skinvisible’s technology Invisicare, a patented polymer delivery system for topical dermatology and consumer goods products. The product has

The current collaboration follows previous agreements, initially started in 2004, and extends the partnership between both the two parties for three years. The tie up will provide support

The clinical study is being directed by Steffen Weikert, assistant director of the clinic for Urology at the Charite of Berlin. The primary goal of this study is

SurModics said that Maharaj will also serve as a member of SurModics’ board of directors. Maharaj, who most recently served as president and CEO of Arizant, will replace

SurModics Pharmaceuticals, which was formed following the acquisition of Brookwood Pharmaceuticals in July 2007, is a product-focused player in drug delivery, providing a range of technology solutions to